AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
-- Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan --
AgomAb Therapeutics N.V. announced today the closing of a $74
million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth of the company's pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with the financing round, a Redmile representative will join the Board of Directors.

Related Keywords

France , Tolga Hassan , Kostenloser Wertpapierhandel , Tim Knotnerus , Laura Mittmann , Philippe Wiesel , John Haurum , Redmile Group , Head Of Corporate Development At Galapagos , Trophic Communications , Boehringer Ingelheim Venture Fund , Cormorant Asset , Advent France Biotechnology , Andera Partners , Omnes Capital , Chief Executive Officer , Hepatocyte Growth Factor , Chief Medical Officer , Chief Business , Corporate Development , Chief Financial Officer , Agomab Therapeutics , Stephanie May , Agomab , Therapeutics , Raises , Million , Series , Advance , Regenerative , Pathway , Modulators , பிரான்ஸ் , டோல்கா ஹாசன் , தலை ஆஃப் பெருநிறுவன வளர்ச்சி இல் க்யாலபாகொஸ் , போஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதி , கர்மரண்ட் சொத்து , தலைமை நிர்வாகி அதிகாரி , தலைமை மருத்துவ அதிகாரி , தலைமை வணிக , பெருநிறுவன வளர்ச்சி , தலைமை நிதி அதிகாரி , மாற்றாந்தாய் இருக்கலாம் , சிகிச்சை , மில்லியன் , தொடர் , மீளுருவாக்கம் , நடைபாதை ,